DRUG
A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)
Status
Completed
Phase
Phase 1
Enrollment
30
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this study is to assess the study medication blood levels after administration of a single oral capsule of Bendavia at one of three dose levels. The effects of Bendavia on the volunteers will also be assessed.
Interventions
Treatment arms and agents.
DRUG
Bendavia 50mg
DRUG
Bendavia 100mg
DRUG
Placebo
Timeline
From registration to results.
First posted
Dec 21, 2012
Study start
Nov 2012
Primary completion
Jan 2013
Study completion
Feb 2013
Results posted
Not reported
Registry updated
Feb 6, 2013
Outcomes
What the study measures.
Primary outcomes
Mean peak plasma concentration (Cmax) of Bendavia (ng/ml) in each cohort.
Time frame · Immediately prior to dosing (0hr) to 48 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36, and 48 hours post-dose will be assessed for Bendavia plasma concentrations. Mean Cmax is defined as the mean of maximum concentration reported for each subject by cohort.
Mean Area Under the Curve (AUC) for Bendavia (hr.ng/ml) in the time from dosing to final plasma sample in each cohort.
Time frame · Immediately prior to dosing (0hr) to 48 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36, and 48 hours post-dose will be assessed for Bendavia plasma concentrations. AUC (0-last) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia is defined as the mean of AUC (0-last) reported for each subject by cohort.
Mean Time post-dose of the peak plasma concentration (Tmax) of Bendavia (hours) in each cohort.
Time frame · Immediately prior to dosing (0hr) to 48 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36, and 48 hours post-dose will be assessed for Bendavia plasma concentrations. Mean Tmax is defined as the mean of time to reach maximum plasma concentration reported for each subject by cohort.
Mean apparent clearance (CL/F) of Bendavia (ml/hr/kg) in each cohort.
Time frame · Immediately prior to dosing (0hr) to 48 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36, and 48 hours post-dose will be assessed for Bendavia plasma concentrations. CL/F will be calculated using validated pharmacokinetic analysis software and mean CL/F for Bendavia is defined as the mean of CL/F reported for each subject by cohort.
Mean Volume of Distribution (Vd/F) of Bendavia (ml/kg) in each cohort.
Time frame · Immediately prior to dosing (0hr) to 48 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36, and 48 hours post-dose will be assessed for Bendavia plasma concentrations. Vd/F will be calculated using validated pharmacokinetic analysis software and mean Vd/F for Bendavia is defined as the mean of Vd/F reported for each subject by cohort.
Mean Half Life(t1/2) of Bendavia (hours) in each cohort.
Time frame · Immediately prior to dosing (0hr) to 48 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36, and 48 hours post-dose will be assessed for Bendavia plasma concentrations. t1/2 will be calculated using validated pharmacokinetic analysis software and mean t1/2 for Bendavia is defined as the mean of t1/2 reported for each subject by cohort.
Secondary outcomes
Mean Area Under the Curve (AUC) for Bendavia metabolite M1 (hr.ng/ml) in the time from dosing to final plasma sample in each cohort.
Time frame · Immediately prior to dosing (0hr) to 48 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36, and 48 hours post-dose will be assessed for Bendavia metabolite M1 plasma concentrations. AUC (0-last) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M1 is defined as the mean of AUC (0-last) reported for each subject by cohort.
Mean Area Under the Curve (AUC) for Bendavia metabolite M2 (hr.ng/ml) in the time from dosing to final plasma sample in each cohort.
Time frame · Immediately prior to dosing (0hr) to 48 hours post-dose
Blood drawn at pre-dose (immediately prior to study drug ingestion), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 36, and 48 hours post-dose will be assessed for Bendavia metabolite M2 plasma concentrations. AUC (0-last) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M2 is defined as the mean of AUC (0-last) reported for each subject by cohort.
Mean change in concentration of urinary 8-isoprostane (pg/mg creatinine) from pre-dose through to 48 hours post-dose for each cohort.
Time frame · Prior to dosing (0hr) to 48 hours post-dose
Spot urine samples will be collected at pre-dose, 12, 24 and 48 hours post-dose for assay of 8-isoprostane (8-EPIPGF2a) and creatinine. Change from baseline value at each time point assessed will be calculated for each subject. Mean change from baseline is defined as the mean of the change in 8-EPIPGF2a/creatinine for each subject by cohort.
Mean change in concentration of urinary 8-hydroxy-2-deoxyguanosine (ng/mg creatinine) from pre-dose through to 48 hours post-dose for each cohort.
Time frame · Prior to dosing (0hr) to 48 hours post-dose
Spot urine samples will be collected at pre-dose, 12, 24 and 48 hours post-dose for assay of 8- hydroxy-2-deoxyguanosine (8-OHDG) and creatinine. Change from baseline value at each time point assessed will be calculated for each subject. Mean change from baseline is defined as the mean of the change in 8-OHDG/creatinine for each subject by cohort.
Number of adverse events observed with and without Bendavia
Time frame · From time of study drug administration to End of Study (Day 3)
Adverse events will be tabulated by treatment group. No statistical analysis will be performed.
Mean change from baseline in High Sensitivity C-Reactive Protein (hs-CRP; ng/L) through 48 hours post-dose.
Time frame · Pre-dose to 48 hours post-dose
hs-CRP will be evaluated prior to (Baseline) and after (12, 24 and 48 hours) study drug administration. Change from baseline value at each time point assessed will be calculated for each subject. Mean change from baseline is defined as the mean of the change in hs-CRP for each subject by cohort.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Healthy adult males or females aged between 18 and 65 years of age with signed informed consent. * Women who are not post-menopausal (without menstrual bleed for \>24 months) or surgically sterile must have a negative serum pregnancy test at screening and within 24 hours of treatment with understanding (through informed consent process) to not become pregnant over the duration of the study and must agree to employ an effective form of birth control for the duration of the study. * Acceptable forms of birth control are: double-barrier contraceptives (condom, diaphragm with spermicide) or intra-uterine device 1 week prior to and at least 30 days post treatment even if hormonal contraceptives are used. Exclusion Criteria: * Serum sodium level below the lower limit of the site's clinical laboratory normal range at the study qualification visit, * Clinically significant laboratory abnormalities as determined by the Principal Investigator at laboratory screening * Creatinine clearance calculated by the Cockcroft and Gault method calculated to be \<90 mL/min for males and \<80 mL/min for females * Clinically significant abnormalities on physical examination, * Body weight less than 60 or greater than 80 kg and a body mass index of less than 18 kg/m2 or greater than 32 kg/m2, * Any disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems, * History of seizures or history of epilepsy, * History of serious (Principal Investigator judgment) mental illness, * Participant in any research involving investigational product within 30 days before planned date of drug administration, * Positive serology for human immunodeficiency virus type 1 or 2, hepatitis B surface antigen, or hepatitis C, * Fever greater than 37.5°C at the time of planned dosing, * Suspicion, or recent history, of alcohol or substance abuse, * Donated blood or blood products within the past 30 days, * Women who are pregnant or breastfeeding, * Employee or family member of the investigational site, * Subjects who currently smoke cigarettes, cigars, pipes or chew tobacco products or who have used any tobacco product in the 30 days prior to screening, * Subjects who are either unwilling to agree to refrain from use or found to be using: * Alcohol, caffeine, xanthine-containing food or beverages, nicotine products and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement period * Prescription medications from 14 days prior to, and 7 days post, dose (excluding hormonal contraceptives) * Hormonal contraceptives without concomitant use of double-barrier contraceptives (condom, diaphragm with spermicide) for a period of 7 days prior to, and 30 days post, dose * Subjects having previous exposure to Bendavia
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Clinical Pharmacology of Miami
Miami, Florida, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Elamipretide.
NCT IDStudyPhase / statusEnrollmentUpdated
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Stealth BioTherapeutics Inc. · Barth Syndrome
Phase 4
Recruiting
48
2026-07
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics Inc. · Age Related Macular Degeneration (ARMD)
Phase 3
Active, not recruiting
313
2026-05
FRDA Investigator Initiated Study (IIS) With Elamipretide
Children's Hospital of Philadelphia · Friedreich Ataxia
Phase 1 / Phase 2
Completed
20
2025-12
Study of Healthy Aging and Physical Function With Elamipretide
David Marcinek · Aging, Healthy
Phase 2
Recruiting
30
2025-12
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Stealth BioTherapeutics Inc. · Mitochondrial Myopathies · Mitochondrial Pathology
Phase 3
Completed
102
2025-10
An Intermediate Size Expanded Access Protocol of Elamipretide
Stealth BioTherapeutics Inc. · Mitochondrial Diseases · Barth Syndrome
Not applicable
Available
—
2025-02
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Stealth BioTherapeutics Inc. · Age-related Macular Degeneration
Phase 2
Completed
176
2024-07
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
Stealth BioTherapeutics Inc. · Barth Syndrome
Phase 2 / Phase 3
Completed
12
2024-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.